PubMed · 11468260
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R M Kisabeth. 2001. Laboratory adaptations--changing expectations.. https://pubmed.ncbi.nlm.nih.gov/11468260/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Over the past 10 years, capillary electrophoresis (CE) is an analytical tool that has shown great promise in replacing many conventional clinical laboratory methods, especially electrophoresis and high performance liquid chromatography (HPLC). The main attraction of CE was that it was fast, used small amounts of sample and reagents, and was extremely versatile, being able to separate large and small analytes, both neutral and charged. Because of this versatility, numerous methods for clinically relevant analytes have been developed. However, with the exception of the molecular diagnostic and forensic laboratories CE has not had a major impact. A possible reason is that CE is still perceived as requiring above-average technical expertise, precluding its use in a laboratory workforce that is less technically adept. With the introduction of multicapillary instruments that are more automated, less technique-dependent, in addition to the availability of commercial and cost effective test kit methods, CE may yet be accepted as a instrument routinely used in the clinical laboratories. Thus, this review will focus on the areas where CE shows the most potential to have the greatest impact on the clinical laboratory. These include analysis of proteins found in serum, urine, CSF and body fluids, immunosubstraction electrophoresis, hemoglobin variants, lipoproteins, carbohydrate-deficient transferrin (CDT), forensic and therapeutic drug screening, and molecular diagnostics.
Steroid sulphatase inhibitors which decrease or prevent the biosynthesis of oestrogens, potentially have an important role in the treatment of breast cancer in postmenopausal women. The non-steroidal sulphatase inhibitor 667 COUMATE has been shown to be active both in vitro and in vivo. The pharmacokinetics of this drug have not been investigated. In preparation for the clinical evaluation of this agent, a sensitive and robust reversed phase high-performance liquid chromatography (HPLC) method was developed for the detection of 667 COUMATE in biological fluids. The sulphatase inhibitor was extracted from plasma with diethyl ether and separated from putative metabolites and endogenous plasma components with a C3-phenyl column. Using this method an extraction efficiency of 76+/-5% and a limit of detection of less than 0.1 ng/ml was achieved. The stability of this agent was investigated under different pH conditions and during storage in plasma at room temperature or -20 degrees C. 667 COUMATE was found to be stable when stored in acidified plasma (pH 4.5) at -20 degrees C. In conclusion, the HPLC method developed is a reproducible and sensitive assay that will enable quantitation of the potent non-steroidal sulphatase inhibitor 667 COUMATE in biological fluids in the forthcoming Phase I clinical trial.
The measurement of creatinine concentrations in peritoneal dialysate is important for evaluating the effectiveness of peritoneal dialysis treatment. However, peritoneal dialysate often contains glucose, which has been reported to interfere with the measurement of creatinine concentrations in some creatinine assays. In this study creatinine concentrations in solutions containing increasing glucose concentrations (0-250 mmol/L) were evaluated using an enzymatic method. No relevant interference from glucose was observed. The creatinine concentration recovery percentages at creatinine concentrations of 250, 500, and 750 micromol/L in dialysate samples containing 250 mmol/L glucose were 101.9%, 101.6%, and 101.0%, respectively, and 101.64%, 102.2%, and 99.8%, in water samples (0 mmol/L glucose). The measured creatinine concentrations in dialysate samples at constant glucose concentrations were linear at 0-1071 micromol/L creatinine, and the linear regression coefficient was 0.99. It is concluded that the enzymatic method described is reliable in measuring creatinine concentrations in dialysate containing glucose, and that the method can be used to evaluate the effectiveness of peritoneal dialysis treatment.